Jerez Joaquín, Goldschmidt Valentina, Guerra María Carolina, Briones José Luis, Torres Carlos, Hidalgo Sebastián, Gazitúa Raimundo
Department of Hematology Fundación Arturo López Pérez, Chile.
Resident of Hematology, Universidad de los Andes, Chile.
Leuk Res Rep. 2023 Dec 12;21:100405. doi: 10.1016/j.lrr.2023.100405. eCollection 2024.
Acute lymphoblastic leukemia represents 20% of acute leukemias in adults. Currently, there is limited data in Chile regarding the clinical, cytogenetic, and prognostic characteristics of this condition.
This is a retrospective, observational, and descriptive study of 67 patients treated for acute lymphoblastic leukemia at the Arturo Lopez Perez Foundation between 2018 and 2021. The main objective is to evaluate epidemiological and clinical characteristics, as well as identifying factors associated with improved overall survival and/or progression-free survival.
88% of the cases were B-lineage, mainly the common B phenotype. Cytogenetic analysis was performed in less than 50% of the patients, with lower yield than expected according to the literature. Molecular testing was performed in 86.5% of the patients, with the most frequent alteration being BCR-ABL. No study was performed to search for Ph-like abnormalities. The rate of complete response after induction was 83.3%, the majority of patients having negative minimal residual disease. Only 12% of the patients received consolidation with allogenic bone marrow transplant. At 2 years, the overall survival was 69% and the progression-free survival was 59%.
The results in terms of overall survival and progression-free survival are similar to those reported in the literature. Important diagnostic gaps prevent adequate prognostic characterization. Allogeneic consolidation transplantation was performed in a lower percentage than expected, highlighting the national deficit in access to this treatment.
急性淋巴细胞白血病占成人急性白血病的20%。目前，智利关于这种疾病的临床、细胞遗传学和预后特征的数据有限。
这是一项对2018年至2021年期间在阿图罗·洛佩斯·佩雷斯基金会接受急性淋巴细胞白血病治疗的67例患者进行的回顾性、观察性和描述性研究。主要目的是评估流行病学和临床特征，以及确定与改善总生存期和/或无进展生存期相关的因素。
88%的病例为B系，主要是常见B表型。不到50%的患者进行了细胞遗传学分析，其检出率低于文献预期。86.5%的患者进行了分子检测，最常见的改变是BCR-ABL。未进行寻找Ph样异常的研究。诱导后完全缓解率为83.3%，大多数患者微小残留病为阴性。只有12%的患者接受了异基因骨髓移植巩固治疗。2年时，总生存率为69%，无进展生存率为59%。
总生存期和无进展生存期的结果与文献报道相似。重要的诊断差距妨碍了充分的预后特征描述。异基因巩固移植的比例低于预期，突出了该国在获得这种治疗方面的不足。
